Introduction: The present study aimed to describe characteristics of patients with type 2
INTRODUCTION
Dapagliflozin, a selective sodium-glucose co-transporter-2 inhibitor, reduces renal glucose reabsorption, resulting in glycosuria, improved glucose control, weight reduction and blood pressure [1] . Placebo-controlled randomized clinical trials (RCTs) and comparator studies have shown that dapagliflozin is effective in treatment-naïve patients with type 2 diabetes (T2D) [2, 3] as well as add-on therapy for patients with inadequate glycemic control while taking metformin [1, [4] [5] [6] , sitagliptin (with or without metformin) [7] , sulphonylurea (with or without metformin) [8, 9] and insulin [10] .
Dapagliflozin shows similar efficacy when used as dual therapy with metformin or insulin, and in triple therapy with other oral glucose-lowering drugs [1, 4-8, 10, 11] .
However, clinical trials are not necessarily representative of the patient population treated in routine care. For example, up to 39% of T2D patients are ineligible based on age alone for trials that have the most stringent inclusion and exclusion criteria [12] . Observational studies with minimal eligibility criteria allow the assessment of use and outcomes in the wider population and have stronger external validity. This observational study aimed to describe the characteristics of patients with T2D in primary care in the UK who received their first prescription for dapagliflozin. The study also aimed to quantify the changes in glycated hemoglobin (HbA 1c ), body weight and blood pressure in patients after being initiated on dapagliflozin and sought information on the clinical reasons why the prescriber added dapagliflozin to insulin and resulting changes in insulin dose.
METHODS
The patient data for this retrospective observational study were obtained from the Clinical Practice Research Datalink (CPRD), which contains anonymized longitudinal patient records collected from more than 12 million patients across the UK [13] . Patients were included in the study if they: (1) had a first prescription for dapagliflozin between November 2012 and September 2014; (2) had a Read code for T2D (Supplementary material S1); (3) were registered with a practice for at least 6 months before starting dapagliflozin; and (4) remained registered for at least 3 months after initiation. A questionnaire (Supplementary material S2) was sent to the general practices of the subset of patients prescribed dapagliflozin as add-on to insulin to ascertain the clinical reason for prescribing dapagliflozin and the dose of insulin before and after dapagliflozin initiation.
Statistical Methods
Eligible data were analyzed using descriptive statistics. Changes in HbA 1c , body weight and systolic and diastolic blood pressure were analyzed for those patients with a measurement before receiving dapagliflozin and at least one measurement during the year after the first dapagliflozin prescription. Results were grouped by time since dapagliflozin initiation: 14-90 days; 91-180 days; and [180 days (up to 365 days).
Baseline characteristics and follow-up variables were described by frequency and percentage distributions. Continuous and count variables were given using mean [±standard deviation (SD)], median (quartiles) and 95% confidence intervals (CIs). All analyses were performed using SAS version 9.2 (SAS Institute, Inc., Cary, NC, USA).
Logistic regression models (reporting Odds Ratios, ORs) were used to examine patient characteristics associated with weight change and achieving HbA 1C targets. The model included only measures recorded 14-365 days after dapagliflozin initiation while patients were on treatment. If patients had more than one measure after dapagliflozin initiation, only the first was examined.
Compliance with Ethics Guidelines
This was an observational, retrospective study using anonymized data from CPRD, which holds ethical approval for observational studies. The Independent Scientific Advisory Committee for Medicines and Healthcare products Regulatory Agency (Protocol Number 14_236AMn) approved this study.
This article is based on observational data and does not involve any new studies of human or animal subjects performed by any of the authors.
RESULTS

Patient Characteristics
Of 2401 patients who received at least one prescription for dapagliflozin in the study period, 1732 fulfilled the inclusion criteria with sufficient follow-up (C3 months) to enable description of co-prescribed medicines (Fig. 1) . HbA 1c values were recorded for 1091 patients, body weight was recorded in 970 and blood pressure in 851 patients before the first prescription of dapagliflozin and during dapagliflozin treatment.
The mean age of the patients (57.9% male) included in the analysis was 57.5 (SD 10.5) years (Table 1) . At baseline, mean HbA 1c was 80.1 (SD 17.9) mmol/mol (9.5%) and the mean weight was 103.1 (SD 22.9) kg. The mean time since T2D diagnosis was 9.5 (SD 6.0) years and 36.9%
of patients had a history of retinopathy, 20.4% a history of neuropathy and 9.8% a history of nephropathy.
Dapagliflozin Treatment
Within the first 3 months after initiation, (Fig. 3b) . No differences were seen in the pattern of HbA 1c reductions when stratified by baseline BMI (Fig. 3c) . 
Initiation of Dapagliflozin
In the 108 patients for whom sufficient questionnaire data were recorded to assess daily insulin dose at dapagliflozin initiation, 32 (29.6%) patients received long-acting insulin only (mean 70. 4 Although an observational study population will not map exactly to any RCT, there are clinical trials in which patients were treated with similar combinations of therapy to the most common treatment groups in our study.
First, for example, in patients treated with metformin (C1500 mg per day), add-on of dapagliflozin (10 mg) reduced HbA 1c by 8.7 mmol/mol (unadjusted difference) (0.79%) compared with 3.2 mmol/mol (0.30%) with placebo after 24 weeks [1] . Second, in a controlled trial, patients treated with dapagliflozin added to metformin plus sulfonylurea showed a placebo-subtracted reduction in HbA 1c of 7.5 mmol/mol (0.69%) after 24 weeks [9] . Third, T2D patients who were inadequately controlled by insulin with or without other oral glucose-lowering drugs and who received dapagliflozin, mean HbA 1c reductions at week 24 were 10.5 mmol/mol (0.96%) with dapagliflozin 10 mg versus 4.3 mmol/mol (0.39%) with placebo [11] . The reductions in HbA 1c were similar in the present study, which confirms the consistency of effects of dapagliflozin in trial and the real world use.
The numerically greater decreases in HbA 1c observed in this real-world evidence study could be explained in part by the higher baseline values, this is consistently seen in most trials of glucose-lowering treatments, irrespective of the treatment used [1, 3, 9, 14] . The reasons in this dataset may relate in part to greater glucosuria at higher blood glucose levels and statistical effects such as regression to the mean, although the precise cause is not fully understood.
Reductions in HbA 1c recorded after a longer treatment with dapagliflozin were generally larger than those recorded earlier in the course of treatment, which again is consistent with long-term controlled trials [5] . However, the regression analysis shows that those patients with lower HbA 1c values before treatment were more likely to reach targets of B58.5 mmol/mol (7.5%) and B53.0 mmol/mol (7%) than those with very high values. In addition, the regression analysis suggested treatment for 181 days and longer was more likely to be associated with the achievement of HbA 1c targets of B58.5 mmol/mol (7.5%), but might also reflect a bias where patients who are responding well are more likely to persist with treatment. Older patients and those with very long duration diabetes seemed less likely to have a good HbA 1c response. This might reflect renal function, which declines with age and duration of diabetes. However, renal function was not assessed in the regression analysis.
In clinical trials, significant weight reductions of 1.5-2.1 kg (placebo subtracted) have been reported in patients treated with dapagliflozin (10 mg) as add-on to metformin with or without sulphonylurea or insulin over 24 weeks [1, 9, 11] . In longer studies, weight appeared to stabilize after 24 weeks [4, 11] . The present study observed weight reductions of 5.4 kg (add-on to metformin), 4.3 kg (triple therapy) and 2.7 kg (add-on to insulin) at 3-6 months and greater reductions in patients treated beyond 6 months (6.3, 4.4 and 3.2 kg, respectively), numerically greater than those seen in the RCT. This might be influenced by the relatively high baseline values in our study:
McGovern et al. showed that a higher BMI at baseline was associated with greater weight loss [15] . In this study, BMI at baseline was not associated with weight loss. However, weight loss of C3 and C5% was associated with treatment with dapagliflozin for 91 days or longer, and with dual therapy with dapagliflozin and metformin. The smaller reduction in the present study presumably reflects the population, of whom only 58% had hypertension.
The median duration of therapy in this study was 10.8 months, consistent with an acceptable tolerability profile; however, no data were collected on tolerability. In a previous clinical study, 15 .4% of patients receiving dapagliflozin (10 mg daily) added to metformin and 4.4% of those taking placebo and metformin discontinued due to adverse events during 102 weeks' treatment [5] . An observational hospital study reported that 22% of patients discontinued dapagliflozin due to side effects and 52% stopped or reduced the dose of at least one other diabetes medication [15] .
Whereas limited external validity compromises many large trials of glycemic control among T2D patients [12] , the CPRD database captures a representative sample of the UK population of over 12 million people [13] from 680 general practices. The present alignment of data from our observational study with those from RCT suggests that the findings are robust and could be generalized to a UK primary care population. Furthermore, most patients not on insulin are not advised to self-monitor blood glucose so may not detect minor hypoglycemic episodes if they occur. Many hypoglycemic episodes are treated by ambulance crews without hospital admission and this information is not captured in the GP record [18] . The majority of patients in this study were not prescribed insulin.
Secondary care data would be required to identify severe hypoglycemic events leading to hospitalizations. Although, CPRD primary care data can be linked to secondary care data, there is incomplete linkage and a lag in follow-up.
The lag in follow-up is a particular problem when examining medications which have a relatively recent launch date like dapagliflozin. Rates of hypoglycemia in RCTs when dapagliflozin was added to metformin or used as monotherapy were similar to placebo [1] ; and over 2 years there was also no difference when used in combination with insulin [19] . 
